First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
November 21, 2024 05:07 ET
|
Pentixapharm Holding AG
BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that...
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
November 20, 2024 07:00 ET
|
CYTOMED THERAPEUTICS LIMITED
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical...
Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials
November 16, 2024 17:40 ET
|
Foundation for Sarcoidosis Research
FSR secured clarification from the U.S. Department of Labor ensuring FMLA coverage for employees participating in clinical trials.
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 15, 2024 07:29 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with...
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024 16:15 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein...
Aviv Clinics Unveils Compelling Results on Treatment for Veterans Suffering from Post-Traumatic Stress Disorder
November 13, 2024 08:52 ET
|
Aviv Clinics
ORLANDO, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain health clinics in the world, shares the results of a groundbreaking study revealing a specialized...
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
November 05, 2024 09:00 ET
|
ImCheck Therapeutics SAS
ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics...
Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease
November 04, 2024 08:57 ET
|
Royal Philips
With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery...
Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
November 04, 2024 07:30 ET
|
Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...